Results 11 to 20 of about 1,033,768 (122)

Resistant and refractory migraine – two different entities with different comorbidities? Results from the REFINE study [PDF]

The Journal of Headache and Pain
Background Resistant and refractory migraine are commonly encountered in specialized headache centers. Several comorbidities, mostly psychiatric conditions, have been linked to migraine worsening; however, there is little knowledge of the comorbidity ...
C. Rosignoli, R. Ornello, V. Caponnetto, A. Onofri, S. Avaltroni, M. Braschinsky, O. Šved, R. Gil-Gouveia, C. Lampl, J. Paungarttner, P Martelletti, W. D. Wells-Gatnik, I. P. Martins, D. Mitsikostas, L. Apostolakopoulou, G. Nabaei, A. Ozge, D. B. Narin, P. Pozo-Rosich, A. Muñoz-Vendrell, M. P. Prudenzano, M. Gentile, K. Ryliskiene, J. Vainauskiene, M. Sanchez del Rio, F. Vernieri, G. Iaccarino, M. Waliszewska-Prosol, S. Budrewicz, M. Carnovali, Z. Katsarava, S. Sacco   +31 more
doaj   +7 more sources

Treatment of Medical Therapy-Resistant Vestibular Migraine with Cranial Osteopathy: A Case Report [PDF]

International Journal of Traditional and Complementary Medicine Research, 2021
Vestibular migraine is a variant of migraine with episodic vestibular symptoms. Diagnostic criteria were determined in 2012 and the term vestibular migraine was used. Lifetime prevalence in adults is calculated as 1%.
Yaser Said Cetin, Seyhmus Kaplan
doaj   +5 more sources

Efficacy and safety of ultrasound-guided peripheral nerve blocks in management of chronic resistant migraine

The Journal of Headache and Pain
Background Migraine is a common primary headache disorder with different treatment modalities emerging as ultrasound guided peripheral nerve blocks. We compared the efficacy and safety of ultrasound guided bilateral sphenopalatine ganglion (SPG) block ...
Nourhan Abdelmohsen Taha, Mai Fathy, Ahmed Elsadek, Tamer Hussein Emara, Sherien Mohamed Farag, Ramez Reda Moustafa, Mohamad Osama Abdulghani   +6 more
doaj   +2 more sources

Migraine: Diagnosis, treatment and understanding c1960-2010 [PDF]

, 2014
seminar transcriptThere are around eight million migraine sufferers in the UK today. This Witness Seminar looked at the last 50 years of research into the diagnosis and treatment of the condition and the changing attitudes of the medical profession ...
Overy, C, Tansey, EM
core   +4 more sources

2025 Highlights in Resistant and Refractory Migraine

Cephalalgia
Jennifer V Robblee
exaly   +3 more sources

Breaking the cycle: unraveling the diagnostic, pathophysiological and treatment challenges of refractory migraine

Frontiers in Neurology, 2023
BackgroundRefractory migraine is a poorly described complication of migraine in which migraine has chronified and become resistant to standard treatments.
Jennifer Robblee
doaj   +1 more source

Effects of Topiramate in the Prevention of Drug Resistant Migraine Headache

Armaghane Danesh Bimonthly Journal, 2009
Introduction & objective: Migraine is the most common cause of headache. The aim of the present study was to evaluate the effects of topiramate (TPM) in the prevention of drug-resistant migraine headache.
H Khani, M Abedini, A Zarvani, A Azadmarzabadi, A Roshanbakhash, R Roshanbakhash, A Ghorbani   +6 more
doaj   +1 more source

Metabolic syndrome and insulin resistance in migraine [PDF]

The Journal of Headache and Pain, 2012
Metabolic syndrome is associated with migraine but there is no study comparing the characteristics of migraine with and without metabolic syndrome from Southeast Asia. This study was therefore undertaken to compare the clinical characteristics of migraine in patients with and without metabolic syndrome and insulin resistance.
Bhoi, Sanjeev K., Kalita, Jayantee, Misra, Usha K.   +2 more
openaire   +2 more sources

Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis

The Journal of Headache and Pain, 2022
Background Controlled and real-world evidence have demonstrated the efficacy of calcitonin gene related peptide (CGRP) monoclonal antibodies (MABs) in migraine.
Anna P. Andreou, Matteo Fuccaro, Bethany Hill, Madeleine Murphy, Valeria Caponnetto, Rachael Kilner, Giorgio Lambru   +6 more
doaj   +1 more source

Medium-term real-world data for erenumab in 177 treatment resistant or difficult to treat chronic migraine patients: persistence and patient reported outcome measures after 17–30 months

The Journal of Headache and Pain, 2023
Background Many migraine patients do not respond adequately to conventional preventive treatments and are therefore described as treatment/medically resistant or difficult to treat cases.
Emma Troy, Arif A. Shrukalla, Alina Buture, Katie Conaty, Esther Macken, Roisin Lonergan, Jane Melling, Niamh Long, Eamonn Shaikh, Kieran Birrane, Esther M. Tomkins, Peter J. Goadsby, Martin H. Ruttledge   +12 more
doaj   +1 more source